Pfizer Doubles Down on MRNA Tech With Three Deals

Sharing is Caring!

Pfizer Inc has signed three deals to broaden the use of the messenger RNA technology (mRNA) that its COVID-19 vaccine was based on, including a pact worth as much as $1.35 billion with gene-editing specialist Beam Therapeutics.

Pfizer will also collaborate with Codex DNA Inc for an undisclosed sum to leverage the biotech’s proprietary technology, which could enable more efficient development of mRNA-based vaccines, therapeutics and other biopharma products. Its collaboration with private biotech Acuitas Therapeutics will focus on the use of the Vancouver-based company’s lipid nanoparticle (LNP) technology for developing up to ten vaccines or therapeutics. The financial details of the deal were not disclosed

See also  NANCY$ STOCK DEAL$ GO BUST
See also  Moderna/Pfizer vaccine "about 10% effective" against Omicorn 20 weeks after dose 2. Booster efficacy drops. Likely need a 4th shot.

money.usnews.com/investing/news/articles/2022-01-10/pfizer-joins-beam-therapeutics-to-develop-rare-disease-therapies

Looks like they’re planning on changing mankind (or what’s left of it) for the foreseeable future

Tess

430 views

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.